950160.Kq
The company operates in the healthcare diagnostics segment, developing and commercializing diagnostic solutions for disease detection and monitoring.
Business. The company operates in the healthcare diagnostics segment, developing and commercializing diagnostic solutions for disease detection and monitoring.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare diagnostics segment, developing and commercializing diagnostic solutions for disease detection and monitoring.
The company's capital structure is characterized by a debt-to-equity ratio of 1.24, indicating a moderate reliance on debt financing. Its liquidity position is weak, with a current ratio of 0.24, suggesting limited short-term liquidity to cover immediate obligations. The company holds $47.2 million in cash and equivalents, but this is offset by $55.4 million in long-term debt, resulting in a net cash position of -$8.2 million.
Profitability metrics are severely negative, with a return on equity of -303.22% and a return on assets of -45.83%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. The operating loss of $15.7 million and net loss of $135.4 million further underscore the company's financial distress.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the company's ability to offset losses in one area with gains in another.
The company's growth trajectory is uncertain, with no disclosed revenue growth in the current fiscal year. The absence of positive revenue trends, combined with significant operating and net losses, suggests a challenging outlook for near-term growth. The company's capital expenditures of $82.6 million indicate ongoing investment, but this has not translated into improved financial performance.
The company faces significant liquidity and dilution risks. The liquidity risk is rated as medium, with a weak current ratio and negative net cash position. The dilution risk is rated as low, but the company's financial position may necessitate future equity issuances to fund operations or reduce debt. No recent dilutive events have been disclosed.
Recent events include a strong buy recommendation from one analyst, with a mean price target of $170,000. However, the company's financial performance does not currently support this optimistic outlook. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or financial health.
- The company is experiencing significant financial distress, with large operating and net losses.
- Liquidity is weak, with a current ratio of 0.24 and a negative net cash position.
- Profitability metrics are severely negative, indicating poor returns for shareholders and inefficient asset utilization.
- The company's revenue is concentrated in a single segment, increasing exposure to market-specific risks.
- Analysts have issued a strong buy recommendation, but the company's financial performance does not currently support this outlook.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 950160.KQ Market data — financials · 2026-05-27
- Kolon TissueGene Inc Market data — analyst estimates · 2026-05-27